Mycophenolate mofetil

Pharmacotherapy

Volumn 17, Issue 6, 1997, Pages 1178-1197

  Sievers, Theodore M ^a   Rossi, Stephen J ^b   Ghobrial, Rafik M ^c   Arriola, Edgar ^c   Nishimura, Pamela ^c   Kawano, Marv ^c   Holt, Curtis D ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b GENZYME CORPORATION   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTACID AGENT; AZATHIOPRINE; COLESTYRAMINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS;

ANEMIA; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MONITORING; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NAUSEA; POSTOPERATIVE COMPLICATION; REVIEW; RHEUMATOID ARTHRITIS; VOMITING;

ANIMALS; ARTHRITIS, RHEUMATOID; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; MYCOPHENOLIC ACID;

EID: 0030667454     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Lindholm A, Ohlman S, Albrechtsen D, et al. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993;56:307-15.
2. Koyama H, Cecka JM. Rejection episodes. In: Terasaki P, Cecka JM, eds. Clinical transplants 1992. Los Angeles: UCLA Tissue Typing Laboratory, 1992:391-404.
3. Suzuki S, Kimura T, Ando K, Sawada T, Tamura G. Antitumor activity of mycophenolic acid. J Antibiot 1969;22:297-302.
4. Ohsugi Y, Hirose S, Juji G. Immunosuppressive effect of mycophenolic acid. Prolongation of survival time of skin allografts. Transplantation J 1972;7:257-9.
5. Watts RW. Some regulatory and integrative aspects of purine nucleotide biosynthesis and its control: an overview. Adv Enzyme Regul 1983;21:33-51.
6. Ohsugi Y, Suzuki S, Takagaki Y. Antitumor and immunosuppressive effects of mycophenolic acid derivatives. Cancer Res 1976;36:2923-7.
7. Jones EL, Epinette WW, Hackney VC, Mendendez L, Frost P. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 1975;65:537-42.
8. Marinari R, Fleischmajer R, Schragger AH, Rosenthal AL. Mycophenolic acid in the treatment of psoriasis. Arch Dermatol 1977;113:930-2.
9. Lynch WS, Roenigk HH Jr. Mycophenolic acid for psoriasis. Arch Dermatol 1977;113:1203-8.
10. Spatz S, Rudnicka A, McDonald CJ. Mycophenolic acid in psoriasis. Br J Dermatol. 1978;98:429-35.
11. Gomez EC, Menendez L, Frost P. Efficacy of mycophenolic acid for the treatment of psoriasis. J Am Acad Dermatol 1979;1:531-7.
12. Eppinette W, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. J Am Acad Dermatol 1987;17:962-71.
13. Nelson P, Eugui E, Allison AC. Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid. J Medicinal Chem 1990;33:833-8.
14. Lee W, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990;7:161-6.
15. Morris RE, Hoyt EG, Eugui EM, Allison AC. Prolongation of rat heart allograft survival by RS-61443. Surg Forum 1989;40:337-8.
16. Sollinger HW, Deierhoi MH, Beizer FO, Diethelm AG, Kauffman RS. RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation 1992;53:428-32.
17. Sollinger HW, Belzer FO, Deierhoi MH, et al. RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg 1992;216:51 -19.
18. Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993;56:75-82.
19. Klintmalm GB, Ascher NL, Busuttil RW, et al. RS-61443 for treatment-resistant liver rejection. Transplant Proc 1993;25:697.
20. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60:225-32.
21. European Mycophenolate Mofetil Study Group. Placebocontrolled study of mycophenolate mofetil combined with cyclosporin and corticosteroid for prevention of acute rejection. Lancet 1995;345:1321-5.
22. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61:1029-37.
23. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996;61:722-9.
24. Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three year experience in heart transplantation. J Heart Lung Transplant 1994;13:571-83.
25. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991;23:1101-3.
26. Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981;41:4253-61.
27. Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte selective cytostatic and immunosuppressive effects of mycophenolate acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991;33:161-73.
28. Gregory CR, Pratt RE, Huie P, et al. Effects of treatment with cyclosporine, FK506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular smooth muscle proliferation in vitro and in vivo. Transplant Proc 1993;25:770-1.
29. Morris RE, Wang J, Slum JR, et al. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and non-human primate recipients of heart allografts. Transplant Proc 1991;23:19-25.
30. Steele DM, Hullett DA, Bechstein WO, et al. Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc 1993;25:754-5.
31. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993;11(suppl 8):S117-19.
32. Bumgardner GL, Roberts JP. New immunosuppressive agents. Gastroenterol Clin North Am 1993;22:421-49.
33. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and ester prodrug, mycophenolate mofetil. Immunol Rev 1993;136:5-28.
34. Allison AC, Kowalski WJ, Muller CD, Eugui EM. Mechanisms of action of mycophenolic acid. Ann NY Acad Sci 1993;696:63-87.
35. Allison AC, Hovi T, Watts RWE, Webster ADB. The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp 1977;48:221-7.
36. Natsumeda Y, Carr SF. Human type I and II IMP dehydrogenase as targets. Ann NY Acad Sci 1993;696:88-93.
37. Giblett ER, Anderson JA, Cohen F, Meuwissen HG. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972;2:1067-9.
38. Stryer L. Biosynthesis of nucleotides. In: Stryer L, ed. Biochemistry, 3rd ed. New York: WH Freeman, 1988:602-26.
39. Dayton J, Lindsten T, Thompsom CB, Mitchell BS. Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. J Immunol 1994;52:984-91.
40. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenase. J Biol Chem 1993;268:27286-90.
41. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969;113:515-24.
42. Sweeny MJ, Huffman DH, Esterman MA. Metabolism and biochemistry of mycophenolic acid. Cancer Res 1972;32:1803-9.
43. Lowe JK, Brox L, Henderson JF. Consequences of inhibition of guanine nucleoside synthesis by mycophenolic acid and virazole. Cancer Res 1977;37:736-43.
44. Makara GM, Keseru GM, Katjar-Peredy M, Anderson WK. Nuclear magnetic resonance and molecular modeling study on mycophenolic acid: implications for binding to inosine monophosphate dehydrogenase. J Med Chem 1996;39: 1236-42.
45. Sintchak MD, Fleming MA, Futer O, et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996;85:921-30.
46. Fleming MA, Chambers SP, Connelly PR, et al. Inhibition of IMPDH by mycophenolic acid: dissection of forward and reverse pathways using capillary electrophoresis. Biochemistry 1996;35:6990-7.
47. Sollinger HW, Eugui EM, Allison AC. RS-61443: mechanism of action, experimental and early clinical results. Clin Transplant 1991;5:523-6.
48. Allison AC, Ahlmquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolate acid and an ester prodrug, RS-61443. Transplant Proc 1991;23(suppl 2):10.
49. Zeevi A, Yao G-Z, Venkataramanan R, et al. Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. Transplant Proc 1993;25:781.
50. Lemster B, Woo J, Strednak J, et al. Cytokine gene expression in murine lymphocytes activated in the presence of FK-506, bredinin, mycophenolic acid or brequinar sodium. Transplant Proc 1992;24:2845-6.
51. Zeevi A, Woan M, Yao GZ, et al. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. Transplant Proc 1991;23:2928-30.
52. Grailer A, Nichols J, Hullett D, Sollinger HW, Burlingham WJ. Inhibition of human B cell responses in vitro by RS-61443, cyclosporine A and DAB4861L-2. Transplant Proc 1991;23:314-15.
53. Burlingham WJ, Grailer AP, Hullett DA, Sollinger HW. Inhibition of both MLC and in vitro IgG memory response to tetanus toxoid by RS-61443. Transplantation 1991;51:545-7.
54. Woo J, Zeevi A, Yao GZ, Strednak J, Todo S, Thomson AW. Effects of FK-506, mycophenolic acid, and bredinin on OKT3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. Transplant Proc 1991;23:2939-40.
55. Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM. Mycophenolic acid and brequinar inhibitors of purine and pyrimidine synthesis block the glycosylation of adhesion molecules. Transplant Proc 1993;47:67-70.
56. Lauren AF, Dumont S, Poindron P, Muller CD. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp Hematol 1996;24:59-67.
57. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991;33: 175-83.
58. Ichimura H, Levy JA. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995;211:554-60.
59. Morris RE, Wang J. Comparison of the immunosuppressive effects of mycophenolic acid and the morpholinoethylester of mycophenolic acid (RS-61443) in recipients of heart allografts. Transplant Proc 1991;23:493-6.
60. Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990;22:1659-62.
61. Bechstein WO, Schilling M, Steele DM, Hullett DA, Sollinger HW. RS-61443/cyclosporine combination therapy prolongs canine liver allograft survival. Transplant Proc 1993;25:702-3.
62. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61443: a new, potent immunosuppressive agent. Transplantation 1991;51:27-31.
63. D'Alessandro AM, Rankin M, McVey J, et al. Prolongation of canine intestinal allograft survival with RS-61443, cyclosporine, and prednisone, Transplantation 1993;55: 695-701.
64. Hao L, Calcinaro F, Lafferty KJ, Allison AC, Eugui EM. Tolerance induction in adult mice: cyclosporine inhibits RS-61443-induced tolerance. Transplant Proc 1991;23:733-4.
65. Hao L, Calcinaro F, Gill RG, Eugui EM, Allison AC, Lafferty KJ. Facilitation of specific tolerance induction in adult mice by RS-61443: a new, potent immunosuppressive agent. Transplantation 1992;53:590-5.
66. Gregory C, Morris RE, Pratt R, Billingham M, Shorthouse R. The use of new antiproliferative immunosuppressants is a novel and highly effective strategy for the prevention of vascular occlusive disease [abstr]. J Heart Lung Transplant 1992;11:197.
67. Steele DM, Hullett DA, Bechstein WO, et al. Effects of immunosuppressive therapy of the rat aortic allograft model. Transplant Proc 1993;25:754-5.
68. Schulak JA, Masih R, Krishnamurthi V, Robinson A. Mycophenolate mofetil immunosuppression in rat pancreas allotransplantation. J Surg Res 1996;60:79-83.
69. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996;36: 315-24.
70. Roche Laboratories. Mycophenolate mofetil (CellCept) package insert. Nutley, NJ; 1997.
71. Parker G, Bullingham R, Kamm B, Hale M. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996;36:332-44.
72. Ettenger R, Warshaw B, Menster M, Potter D. Mycophenolate mofetil (MMF) in pediatric (Ped) renal transplantation (Tx): a report of the Fed MMF study group [abstr]. Presented at the 15th annual meeting of the American Society of Transplant Physicians, Dallas, May 26-30, 1996.
73. Hebert MF, Benet LZ, Gomez D, et al. Pharmacokinetics (PK) of oral mycophenolate mofetil (MM) in liver transplant patients [abstr]. Clin Pharmacol Ther 1994;55:164.
74. Hebert MF, Chang T, Linna TJ, Hale MD, Roberts JP. Pharmacokinetics (PK) of intravenous mycophenolate mofetil (MMF) in liver transplant patients [abstr]. Clin Pharmacol Ther 1996;59:184.
75. Brewin TB, Cole MP, Jones CTA, Platt DS, Todd IDH. Mycophenolic acid (NSC-129185): preliminary clinical trials. Cancer Chemother Rep 1972;56:83-7.
76. Lintrup J, Hyltoft-Petersen P, Kundtzon S, Nissen NI. Metabolic studies in man with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother Rep 1972;56:229-35.
77. Deierhoi MH, Kauffman RS, Hudson SL, et al. Experience with mycophenolate mofetil in renal transplantation at a single center. Ann Surg 1993;217:476-84.
78. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995;41:1011-17.
79. Platz KP, Eckhoff DE, Hullett DA, et al. RS-61443 studies: review and proposal. Transplant Proc 1991;23:33-5.
80. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 1993;14:353-80.
81. Bullingham RES, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS-61443): a short review. Transplant Proc 1996;28:925-9.
82. Li S, Yatscoff RW. Improved high-performance liquid Chromatographic assay for the measurement of mycophenolic acid in human plasma. Transplant Proc 1996;28:938-40.
83. Langman LJ, LeGatt DF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Drug Monit Toxicol 1995;41:295-9.
84. Zucker K, Esquenazi V, Rosen A, et al. Unexpected augmentation of MMF pharmacokinetics in renal transplant patients receiving prograf and cellcept in combination therapy, and analogous in vitro findings [abstr]. Presented at the XVI International Congress of the Transplantation Society, Barcelona, August 25-30, 1996.
85. Laskow DA, Deierhoi MH, Orr CL, Curtis JJ, Diethelm AG. The incidence of acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS-61443). Transplantation 1994;57:640-3.
86. Islam MS, Francos GF, Burke JF. Mycophenolate mofetil is effective in the treatment of renal allograft dysfunction due to cyclosporine nephrotoxicity [abstr]. J Am Soc Nephrol 1996;9:1913.
87. First MR, Schroeder TJ, Shah M, Hariharan S, Peddi R, Weiskittel P. A comparison of the safety and efficacy of two immunosuppressive regimens: mycophenolate mofetil, prednisone and cyclosporine and mycophenolate mofetil, prednisone and tacrolimus [abstr]. Presented at the 15th annual meeting of the American Society of Transplant Physicians, Dallas, May 26-30, 1996.
88. Holt C, Goss J, McDairmid S, et al. Efficacy and safety of low dose tacrolimus and mycophenolate mofetil in OLT recipients [abstr]. Hepatology 1996;24 (part 2):173A.
89. Gavlik A, Goldberg MS, Tsaroucha A, et al. Mycophenolate rescue therapy in liver transplant patients [abstr]. Presented at the XVI International Congress of the Transplantation Society, Barcelona, August 25-30, 1996.
90. Stratta RJ, First MR, Egidi F, et al. Simultaneous use of FK-506 and mycophenolate mofetil in pancreas and kidney transplant recipients: a multicenter report [abstr]. Presented at the XVI International Congress of the Transplantation Society, Barcelona, August 25-30,1996.
91. Kirklin J, Bourge RC, Naftel DC, et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 1994;13:444-50.
92. Dhawan A, Kaufman S, Pillen T, et al. Preliminary experience with mycophenolate mofetil as rescue therapy for liver allograft rejection in children [abstr]. Hepatology 1996;24(part 2):304A.
93. Kobashigawa JA, Renlund DG, Olsen SL. Initial results of RS-61443 for refractory cardiac rejection [abstr]. J Am Col Cardiol 1992;19:203A.
94. Trotter J, Washington K, Kohli V, Clavien P. Mycophenolate mofetil is an effective treatment for steroid resistant acute cellular rejection [abstr]. Hepatology 1996;24(part 2):173A.
95. Friese CE, Hebert MF, Osorio RW, et al. Maintenance immunosuppression with prednisone and RS-61443 alone after liver transplantation. Transplant Proc 1993;25:278-98.
96. Eckoff DE, Ingram CO, Crocker RM, Bynon JS. Tacrolimus and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplant patients [abstr]. Hepatology 1996;24(part 2):506A.
97. Stegall MD, Everson GT, Wachs ME, et al. Prednisone withdrawal 14 days after adult liver transplantation - a randomized trial of tacrolimus and cyclosporine with mycophenolate mofetil [abstr]. Hepatology 1996;24(part 2):174A.
98. Stegall MD, Simon M, Wachs M, Kam I. Decreased rejection in simultaneous pancreas kidney transplantation with mycophenolate mofetil - a randomized trial of tacrolimus and cyclosporine [abstr]. Presented at the 15th annual meeting of the American Society of Transplant Physicians, Dallas, May 26-30, 1996.
99. Hebert M, Ascher N, Lake J, et al. Mycophenolate mofetil for prophylaxis against rejection following orthotopic liver transplantation [abstr]. Presented at the XV International Congress of the Transplantation Society, Kyoto, August 28-September 2, 1994.
100. Hassanein T, Freeman J, Oculam CA, Albanese L, Zamora JU, Wahlstrom E. Successful early steroid withdrawal using tacrolimus and mycophenolate protocol for liver transplantation [abstr]. Hepatology 1996;24(part 2):521A.
101. Fisher RA, Shiffman ML, Naar JD, et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus induction following orthotopic liver transplantation [abstr]. Hepatology 1996;24(part 2):511A.
102. John D, Morgan G, Diflo T, Simons C, Tobias H, Teperman L. Induction immunotherapy in liver transplantation with mycophenolate mofetil and steroids [abstr]. Hepatology 1996;24(part 2):529A.
103. Deierhoi MH, Sollinger HW, Diethelm AG, Belzer FO, Kauffman RS. One-year follow-up results of a phase I trial of mycophenolate mofetil (RS-61443) in cadaveric renal transplantation. Transplant Proc 1993;25:693-4.
104. Takahashi K, Ochiai T, Uchida K, et al. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. Transplant Proc 1995;27:1421-4.
105. Preise CE, Hebert M, Osorio RW, et al. Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation. Transplant Proc 1993;25: 1758-9.
106. Schiff MH, Goldblum R, Rees MMC. New DMARD mycophenolate mofetil (myco-m), efficacy treats refractory rheumatoid arthritis (RA) patients for one year [abstr]. Arthritis Rheum 1991;34:S89.